K-Bio Built the World’s No. 1 CDMO, but Its Media and Resins Are Still Imported

Samsung Biologics has now reached the world’s largest antibody drug CDMO production capacity, climbing to a total of about 845,000 liters. With Plant 5 and the acquisition of Rockville in the U.S. added to the mix, the language of scale has already reached the global standard. ST Pharm, ranked No. 1 in Asia and No. 3 globally in oligonucleotide API CDMO, has begun expanding its second oligo plant, while SK bioscience is pushing both vaccine CDMO and its own vaccine business at the same time, even moving ahead with the acquisition of Germany’s IDT Biologika. On the surface, Korean biotech now looks like a nation built for production.

But take just one more step inside the factory, and the picture changes. Core process materials and equipment needed to run these massive CDMO facilities—such as cell culture media, purification resins, single-use bags, and bioreactors—still depend heavily on global supply chains led by companies like Cytiva, Thermo Fisher, and Merck. Production capacity may be world-class, but the real levers of cost, lead times, and supply stability remain tied to players outside Korea. Unless this paradox is resolved, K-bio may keep getting bigger, but it is hard to say its industrial foundation is truly complete.

Antibody & Vaccine CDMO — The Scale War in Contract Manufacturing (5 companies)

In antibody and vaccine CDMO, Korean companies have already established a clear presence. Samsung Biologics stands in a league of its own in production capacity, while ST Pharm holds a well-defined position as No. 1 in Asia and No. 3 globally in oligo API. SK bioscience has paired vaccine CDMO with its own vaccine portfolio, and Binex is pursuing both biopharmaceutical CDMO/CMO and synthetic pharmaceuticals, with a revenue mix of roughly 42% CDMO and 58% synthetic drugs. Prestige Biologics is also operating an antibody biopharmaceutical CMO business focused on biosimilar outsourcing, with total culture capacity of 154,000L.

The weak point of Korean CDMOs is not production capacity, but the still-low local sourcing ratio in the process ecosystem needed to fill that capacity. The question of whether they can produce at scale has already been answered. What remains is what they can produce with, how reliably they can produce it, and how resilient that production can be. News of plant expansions is big and flashy, but the real tension on the ground often begins with a supply disruption in a single media item, one resin line, or one batch of consumables. That is why the next chapter after the scale race is raw and process materials.

Company	Core focus
Samsung Biologics	World’s largest antibody drug CDMO production capacity (total ~845,000L) — Plant 5 and acquisition of Rockville, U.S.
ST Pharm	Oligonucleotide API CDMO, No. 1 in Asia and No. 3 globally — expansion of second oligo plant
SK bioscience	Vaccine CDMO + in-house vaccines (cell-culture influenza, COVID) — acquisition of Germany’s IDT Biologika
Binex	Biopharmaceutical CDMO/CMO + synthetic pharmaceuticals (revenue: CDMO ~42%, synthetic ~58%)
Prestige Biologics	Antibody biopharmaceutical CMO — total culture capacity of 154,000L (biosimilar outsourcing)

Process Raw Materials & Inputs — The Hidden Cost Base of CDMOs (Import Dependence) (4 companies)

This is where names like Amicogen, eCell, Pharmicell, and Bionote start to matter. Amicogen, whose core business is specialty enzymes, is also pushing to localize cell culture media and purification resins. That said, its media and resin businesses are still in the early stages of commercialization. eCell is a small domestic specialist focused on localization, dealing in single-use cell culture bags and bioprocess consumables. Pharmicell supplies nucleoside raw materials for oligo and mRNA inputs, while Bionote handles antigen and antibody materials for in vitro diagnostics and also operates in animal diagnostics.

Localization of raw and process materials has clearly begun, but it is still closer to the stage of 'proving substitutability' than to a full-scale production phase that has overturned the global oligopoly structure. That needs to be acknowledged honestly. Media and resins are not just simple consumables; they are deeply tied to process reproducibility, yield, and even regulatory compliance. That is exactly why companies do not easily switch suppliers once one has been validated. Still, standing still is not an option. Supply chain risk does not reveal itself only in times of crisis—it also quietly builds up in everyday cost structures and bargaining power. Even if a mega-CDMO like Samsung Biologics is the global No. 1, can we really say the industry's final puzzle piece is in place if it still depends on imports for most of its critical consumables?

Company	Core focus
Amicogen	Push to localize cell culture media and purification resins + specialty enzymes (core business) — media and resins are still in the early commercialization stage
eCell	Single-use (disposable) cell culture bags and bioprocess consumables — small domestic specialist in localization (unlisted)
Pharmicell	Nucleoside raw materials (for oligo and mRNA inputs) + stem cell therapeutics — KOSPI-listed
Bionote	Antigen and antibody materials for in vitro diagnostics (diagnostic materials) — affiliated with SD Biosensor, also engaged in animal diagnostics

Process Equipment, Analysis & Diagnostics — Measuring Biotech (3 companies)

Equipment, analysis, and diagnostics need to be viewed through the same lens. MicroDigital has single-use bioreactors and spectroscopic analyzers, and most of its current revenue comes from spectroscopy and biomedical products. Curiox Biosystems supplies its Laminar Wash automated sample-prep system for cell analysis to 18 of the world’s top 20 pharmaceutical companies. i-SENS is Korea’s No. 1 blood glucose biosensor company in the self-monitoring blood glucose segment, and it is expanding into continuous glucose monitoring (CGM).

In biotech, the battle is not just about how well you make something, but how precisely you measure it and how consistently you can reproduce it with standardized equipment. That is why equipment and analysis may seem to stand in the background, but in reality they sit at the very center of manufacturing competitiveness. Still, this is another area where some cool-headedness is needed. In MicroDigital’s case, it does have single-use bioreactors, but most revenue still comes from spectroscopy and biomedical products. Curiox Biosystems has a clear edge in automated sample prep, but that does not automatically mean a broad shift toward domestically made equipment across the entire process. The current reality is simply this: more players are emerging and digging deep into one niche at a time.

Company	Core focus
MicroDigital	Single-use bioreactors + spectroscopic analyzers (most revenue still comes from spectroscopy and biomedical products)
Curiox Biosystems	Automated sample prep for cell analysis (Laminar Wash) — supplied to 18 of the world’s top 20 pharmaceutical companies
i-SENS	Korea’s No. 1 blood glucose biosensor company (self-monitoring blood glucose) — expanding into continuous glucose monitoring (CGM)

What to Watch Going Forward

The next phase of competition will not be decided simply by who adds a few more tens of thousands of liters of CDMO capacity. What Samsung Biologics, ST Pharm, and SK bioscience have shown is that Korea has already cleared the production hurdle. The next question is tougher: how much of the ecosystem can be secured domestically—media and resins, single-use consumables, nucleoside raw materials, bioreactors, and analytical equipment. Supply chain security is not some grand slogan; in industrial terms, it is where lead times, costs, validation, and customer trust all intersect.

K-bio’s final assignment is not building more plants, but making those plants less vulnerable through self-reliance in raw and input materials. That said, exaggeration is unhelpful. Amicogen’s media and resin businesses are still in the early stages of commercialization, and domestic consumables makers like eCell are still competing from a relatively small base. But that does not make their significance any smaller. What is needed now is neither the optimism of “it’s already done” nor the cynicism of “it will never happen anyway.” The task is to assess precisely how far things have come and expand, step by step, where domestic substitution is possible in each process. Industry is often remembered through images of massive factories, but real competitiveness is decided by the things you do not see—bags and resins, media and equipment.

※ This article organizes company names, core businesses, and market positioning based on publicly available materials verified online, and some assessments reflect the author’s own views. It is not intended as a direct basis for investment decisions.

Written: July 2026. Ealexandro